Prostate Cancer Surgery Lagged for Black Men During Pandemic
Black men less likely than White men to undergo prostatectomy despite similar COVID - 19 risk factors, biopsy Gleason grade groups (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 26, 2021 Category: Cancer & Oncology Tags: Oncology, Surgery, Urology, Journal, Source Type: news

Prostate Cancer Surgery Lagged for Black Men During Pandemic
MONDAY, July 26, 2021 -- During the initial wave of the COVID-19 pandemic, the likelihood of undergoing surgery for prostate cancer was lower for Black than White patients, according to a study published online July 22 in JAMA Oncology. Adrien N.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 26, 2021 Category: Pharmaceuticals Source Type: news

Just 1% of black men with prostate cancer had the organ removed during pandemic
During COVID-19 lockdowns, just 1% of black prostate cancer patients had their prostate removed compared with 26% of white patients, researchers at Fox Chase Cancer Center found. (Source: the Mail online | Health)
Source: the Mail online | Health - July 22, 2021 Category: Consumer Health News Source Type: news

Prostate cancer treatment among black, white patients during pandemic
This study included 647 patients with untreated nonmetastatic prostate cancer (269 patients during the pandemic and 378 from before the pandemic). During the initial COVID-19 lockdown, only 1% of Black men underwent prostatectomy, while 26% of white patients did. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - July 22, 2021 Category: Infectious Diseases Source Type: news

Lack of After Care Leaves Cancer Patients in'Survivorship Abyss'Lack of After Care Leaves Cancer Patients in'Survivorship Abyss '
Ten years after being diagnosed with prostate cancer, 98% of men are still alive – but many report ongoing adverse effects that make life a struggle.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 21, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Johnson & Johnson Reports Q2 2021 Results
New Brunswick, N.J. (July 21, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter. “Our second-quarter results showcase Johnson & Johnson’s diversified portfolio, driven by strong sales and earnings growth across our Medical Device, Consumer Health and Pharmaceutical businesses,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m so proud of our 136,000 colleagues who remain focused on delivering our medicines and products to patients and consumers around the world, in addition to advancing our pipeline with new product launches and regulato...
Source: Johnson and Johnson - July 21, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

AI detects axillary lymph node metastasis on multiparametric MRI
Deep-learning algorithms can detect axillary lymph node metastasis on multiparametri...Read more on AuntMinnie.comRelated Reading: Abbreviated breast MRI bests mammo, ultrasound for 2nd cancers Breast MRI finds more recurrent cancer Weak supervision yields strong results for AI in breast MRI Is mpMRI equally available to all men at risk of prostate cancer? AI, radiomics can predict cancer in lesions found on breast MRI (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 16, 2021 Category: Radiology Source Type: news

MRI cost-effective for prostate cancer surveillance
Using MRI for active prostate cancer surveillance is more cost-effective tha...Read more on AuntMinnie.comRelated Reading: MRI for prostate cancer screening reduces unnecessary biopsies Black men less likely to undergo MRI before prostate biopsy Is mpMRI equally available to all men at risk of prostate cancer? MRI-first prostate screening could reduce death rates Short MRI exam shows promise for prostate cancer screening follow-up (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 14, 2021 Category: Radiology Source Type: news

Obese Men May Have Better Survival With Advanced Prostate Cancer
Title: Obese Men May Have Better Survival With Advanced Prostate CancerCategory: Health NewsCreated: 7/12/2021 12:00:00 AMLast Editorial Review: 7/13/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - July 13, 2021 Category: Cancer & Oncology Source Type: news

Tool helps predict who will respond best to targeted prostate cancer therapy
A new prognostic tool developed by researchers from theUCLA Jonsson Comprehensive Cancer Center and five other institutionshelps predict which men with advanced metastatic prostate cancer will respond favorably to a novel targeted therapy.The tool,described in a study published today in Lancet Oncology, analyzesa wide spectrum of imaging and clinical data and is intended to assist physicians considering treating patients with Lutetium-177 prostate-specific membrane antigen, or LuPSMA.LuPSMA, which binds to PSMA proteins and delivers targeted radiation to prostate cancer tissue, offers a new option to men with PSMA-positive...
Source: UCLA Newsroom: Health Sciences - July 12, 2021 Category: Universities & Medical Training Source Type: news

Obese Men May Have Better Survival With Advanced Prostate Cancer
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 12, 2021 Category: Cancer & Oncology Tags: Family Medicine, Oncology, Reproductive Medicine, Urology, Nutrition, News, Source Type: news

Better Outcomes for Obese Men With Advanced Prostate Cancer
When men have advanced prostate cancer, obesity might offer something of a survival advantage, a preliminary study suggests. (Source: WebMD Health)
Source: WebMD Health - July 12, 2021 Category: Consumer Health News Source Type: news

MRI-Enhanced Screening Strategy Noninferior for Prostate Cancer ​
MONDAY, July 12, 2021 -- Magnetic resonance imaging (MRI) with targeted and standard biopsy for men with MRI results indicative of prostate cancer is noninferior to standard biopsy for identifying clinically significant prostate cancer, according to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 12, 2021 Category: Pharmaceuticals Source Type: news

Obese Men May Have Better Survival With Advanced Prostate Cancer
MONDAY, July 12, 2021 -- When men have advanced prostate cancer, obesity might offer something of a survival advantage, a preliminary study suggests. Researchers in Italy found that among men with prostate cancer that had spread throughout the... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 12, 2021 Category: General Medicine Source Type: news

MRI for prostate cancer screening reduces unnecessary biopsies
Swedish researchers have found that using MRI for prostate cancer screenin...Read more on AuntMinnie.comRelated Reading: Black men less likely to undergo MRI before prostate biopsy Is mpMRI equally available to all men at risk of prostate cancer? When will PET/MRI live up to its promise? MRI-first prostate screening could reduce death rates Short MRI exam shows promise for prostate cancer screening follow-up (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 12, 2021 Category: Radiology Source Type: news

Monitoring proves better than active treatment for low-risk prostate cancer
(European Association of Urology) Men over 60 with low-risk prostate cancer could spend ten years with no active treatment, have a better sex life as a result, yet still be very unlikely to die from the disease, new research has found. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 11, 2021 Category: International Medicine & Public Health Source Type: news

New concept drug hunts down late-stage prostate cancer
(European Association of Urology) A new class of drug successfully targets treatment-resistant prostate cancers and prolongs the life of patients. The treatment delivers beta radiation directly to tumour cells, is well tolerated by patients and keeps them alive for longer than standard care, found a phase 3 trial to be presented at the European Association of Urology congress, EAU21, today. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 10, 2021 Category: Cancer & Oncology Source Type: news

Obesity increases survival in advanced prostate cancer
(European Association of Urology) Obese patients with a form of advanced prostate cancer survive longer than overweight and normal weight patients, new research has found. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 10, 2021 Category: Cancer & Oncology Source Type: news

Prostate cancer screening using MRI may reduce overdiagnosis of the disease, study finds
Screening for prostate cancer using magnetic resonance imaging and targeted biopsies may reduce misdiagnoses of the disease by up to 50%, a study published Friday by the New England Journal of Medicine found. (Source: Health News - UPI.com)
Source: Health News - UPI.com - July 9, 2021 Category: Consumer Health News Source Type: news

Guideline-Concordant Multimodality Care Tied to Fewer Deaths in High-Risk Prostate Cancer Guideline-Concordant Multimodality Care Tied to Fewer Deaths in High-Risk Prostate Cancer
In high-risk prostate cancer patients with at least one additional adverse feature, guideline-concordant multimodal care was associated with greater prostate cancer-specific survival in a large retrospective study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 9, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

MRI Plus New Score Halves Biopsy Rate for Prostate Cancer MRI Plus New Score Halves Biopsy Rate for Prostate Cancer
Using MRI targeting of lesions along with the Stockholm 3 risk score cut the number of biopsies by 52% compared with the systematic approach.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 9, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

New experimental drug gives hope to men with aggressive prostate cancer
Men with particularly aggressive prostate cancers can be treated more effectively by combining an existing medicine with an experimental drug, research suggests. (Source: Daily Express - Health)
Source: Daily Express - Health - July 9, 2021 Category: Consumer Health News Source Type: news

Adding MRI to Screening Can Cut Prostate Cancer Overdiagnosis in Half
FRIDAY, July 9, 2021 -- One of the big issues in prostate cancer care is overdiagnosis — men who are treated for low-risk, slow-growing tumors that might be better left monitored and untreated. Now, research out of Sweden suggests that having... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 9, 2021 Category: General Medicine Source Type: news

Adding MRI to Screening Can Cut Prostate Cancer Overdiagnosis in Half
Title: Adding MRI to Screening Can Cut Prostate Cancer Overdiagnosis in HalfCategory: Health NewsCreated: 7/9/2021 12:00:00 AMLast Editorial Review: 7/9/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - July 9, 2021 Category: Cancer & Oncology Source Type: news

MRI can cut overdiagnoses in prostate-cancer screening by half
(Karolinska Institutet) Most countries have not introduced nationwide prostate-cancer screening, as current methods result in overdiagnoses and excessive and unnecessary biopsies. A new study by researchers at Karolinska Institutet in Sweden, which is published in The New England Journal of Medicine, indicates that screening by magnetic resonance imaging (MRI) and targeted biopsies could potentially cut overdiagnoses by half. The results are presented today at the European Association of Urology Congress. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 9, 2021 Category: Cancer & Oncology Source Type: news

Tool helps predicts who will respond best to targeted prostate cancer therapy
A new prognostic tool developed by researchers from theUCLA Jonsson Comprehensive Cancer Center and five other institutionshelps predict which men with advanced metastatic prostate cancer will respond favorably to a novel targeted therapy.The tool,described in a study published today in Lancet Oncology, analyzesa wide spectrum of imaging and clinical data and is intended to assist physicians considering treating patients with Lutetium-177 prostate-specific membrane antigen, or LuPSMA.LuPSMA, which binds to PSMA proteins and delivers targeted radiation to prostate cancer tissue, offers a new option to men with PSMA-positive...
Source: UCLA Newsroom: Health Sciences - July 9, 2021 Category: Universities & Medical Training Source Type: news

Cocktail of prostate drugs could shrink tumours and cuts deaths by a QUARTER, trial shows 
Patients given two different prostate cancer drugs were three times more likely to experience complete remission than those given only one, a trial found. (Source: the Mail online | Health)
Source: the Mail online | Health - July 8, 2021 Category: Consumer Health News Source Type: news

New AI tech for early detection of prostate cancer
(RMIT University) Researchers have developed a diagnostic tool that can spot prostate cancer before patients have any symptoms, using artificial intelligence to analyse CT scans in just seconds. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 7, 2021 Category: Cancer & Oncology Source Type: news

Anti-androgen therapy can fuel spread of bone tumours in advanced prostate cancer
(Queensland University of Technology) Anti-androgen therapy is commonly used to treat patients with advanced prostate cancer at stages where the disease has spread to the bones. However, new research has found that anti-androgen treatment can actually facilitate prostate cancer cells to adapt and grow in the bone tumour microenvironment model, which has been developed by QUT biomedical scientists led by Dr Nathalie Bock. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 7, 2021 Category: Cancer & Oncology Source Type: news

Tool helps predicts who will respond best to targeted prostate cancer therapy
(University of California - Los Angeles Health Sciences) A new prognostic tool helps predict which men with advanced metastatic prostate cancer will respond favorably to a novel targeted therapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 7, 2021 Category: Cancer & Oncology Source Type: news

Radioligand Therapy Slows Advanced PSMA+ Prostate Cancer
177Lu - PSMA - 617 added to standard care prolonged imaging - based progression - free survival and overall survival (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 6, 2021 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Radiology, Urology, Journal, Source Type: news

Radioligand Therapy Slows Advanced PSMA+ Prostate Cancer
TUESDAY, July 6, 2021 -- Lutetium-177 (177Lu)-prostate-specific membrane antigen (PSMA)-617 radioligand therapy added to standard care is beneficial for patients with advanced PSMA-positive metastatic castration-resistant prostate cancer, according... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 6, 2021 Category: Pharmaceuticals Source Type: news

Men with terminal prostate cancer could be thrown lifeline by 'doubling up' radiotherapy treatments
One patient in the trial, David Livingstone, 68, was diagnosed in 2016 with prostate cancer. He was given six months to live - but the ex-photographer from Northern Ireland is still alive five years later. (Source: the Mail online | Health)
Source: the Mail online | Health - July 3, 2021 Category: Consumer Health News Source Type: news

Ga-68 PSMA-11 improves outcomes in prostate cancer patients
PET with a gallium-68 (Ga-68) prostate-specific membrane antigen (PSMA)-11 radiotrace...Read more on AuntMinnie.comRelated Reading: Lantheus gets FDA nod for Pylarify PET agent for prostate cancer Hoag launches PET trials for prostate cancer, myeloma Novel radiotracer shows promise for prostate imaging FDA makes history with approval of Ga-68 PSMA-11 PET Point Biopharma to use Lantheus' PyL in clinical trial (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 2, 2021 Category: Radiology Source Type: news

Multimodality care improves treatment outcomes for aggressive prostate cancer
(University of California - Los Angeles Health Sciences) Men with high-risk prostate cancer with at least one additional aggressive feature have the best outcomes when treated with multiple healthcare disciplines, known as multimodality care, according to a UCLA study. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 1, 2021 Category: Cancer & Oncology Source Type: news

Race May Influence Treatment Receipt in Prostate Cancer
In high treatment benefit category, Black men less likely to receive definitive treatment than non - Black men (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 29, 2021 Category: Cancer & Oncology Tags: Oncology, Pathology, Radiology, Surgery, Urology, Journal, Source Type: news

Black Men Less Likely to Get Best Prostate Cancer Treatments
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 29, 2021 Category: Cancer & Oncology Tags: Nursing, Oncology, Reproductive Medicine, Research, Surgery, News, Source Type: news

Study: Black men less likely to receive advanced prostate cancer care than White, Hispanic men
Black men with advanced prostate cancer are 11% less likely to receive aggressive treatments than White and Hispanic men with the disease, a study published Tuesday by the journal Cancer found. (Source: Health News - UPI.com)
Source: Health News - UPI.com - June 29, 2021 Category: Consumer Health News Source Type: news

Black Men Less Likely to Get Best Prostate Cancer Treatments
Researchers analyzed medical records of men treated for prostate cancer by the U.S. Veterans' Health Administration -- most were over 60 with no other serious health issues. (Source: WebMD Health)
Source: WebMD Health - June 29, 2021 Category: Consumer Health News Source Type: news

Race May Influence Treatment Receipt in Prostate Cancer
TUESDAY, June 29, 2021 -- For men with prostate cancer, race seems to influence receipt of definitive treatment, with the association varying in the context of the patient's treatment benefit, according to a study published online June 29 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 29, 2021 Category: Pharmaceuticals Source Type: news

Black Men Less Likely to Get Best Prostate Cancer Treatments
TUESDAY, June 29, 2021 -- Black American military veterans with aggressive prostate cancer who would benefit from surgery or radiation are less likely to get those treatments than men of other races, despite equal access to health care, a new study... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 29, 2021 Category: General Medicine Source Type: news

Telix, Monrol reach agreement on therapeutic isotope supply
Telix Pharmaceuticals announced has inked a global clinical supply agreemen...Read more on AuntMinnie.comRelated Reading: Groups launch registry to promote SPECT for prostate cancer ARTMS, Telix produce PSMA-11 in cyclotron Telix files NDA for prostate cancer PET imaging agent RefleXion, Telix partner on high-risk cancer treatments Companies partner on gallium-68 imaging (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 29, 2021 Category: Radiology Source Type: news

Study sheds light on persistent racial disparities in prostate cancer care in the United States
(NYU Langone Health / NYU Grossman School of Medicine) Black men most likely to benefit from advanced prostate cancer therapies are 11% less likely to get them than non-Black men. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 29, 2021 Category: Cancer & Oncology Source Type: news

Telix, Monrol ink therapeutic isotope supply agreement
Telix Pharmaceuticals announced has inked a global clinical supply agreemen...Read more on AuntMinnie.comRelated Reading: Groups launch registry to promote SPECT for prostate cancer ARTMS, Telix produce PSMA-11 in cyclotron Telix files NDA for prostate cancer PET imaging agent RefleXion, Telix partner on high-risk cancer treatments Companies partner on gallium-68 imaging (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 28, 2021 Category: Radiology Source Type: news

New Therapy for Aggressive Prostate Cancer Improves Survival
The experimental treatment relies on radioactive molecules that seek out tumor cells, a strategy that may be useful against other cancers. (Source: NYT Health)
Source: NYT Health - June 25, 2021 Category: Consumer Health News Authors: Roni Caryn Rabin Tags: your-feed-science Clinical Trials Prostate Cancer Drugs (Pharmaceuticals) Tumors Radiation Deaths (Fatalities) Chemotherapy New England Journal of Medicine Novartis AG Source Type: news

Black men less likely to undergo MRI before prostate biopsy
Black men are less likely to undergo MRI before prostate biopsy than their whit...Read more on AuntMinnie.comRelated Reading: MRI-guided biopsy improves prostate cancer assessment Choline-PET boosts mpMRI for prostate cancer detection Prostate cancer patients prefer mpMRI over biopsy mpMRI reduces unnecessary prostate biopsies Which biopsy method best detects prostate cancer? (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 24, 2021 Category: Radiology Source Type: news

Prostate Cancer Drug Improves COVID-19 Survival in Trial Prostate Cancer Drug Improves COVID-19 Survival in Trial
An experimental prostate cancer drug improved the survival of hospitalized COVID-19 patients in Brazil in a clinical trial, researchers reported on medRxiv ahead of peer review.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 24, 2021 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news

Immunotherapy may be effective for subset of prostate cancer
(Beth Israel Deaconess Medical Center) Researchers report that about a quarter of localized prostate cancers may demonstrate immunologic traits that would allow a substantial number of patients with prostate cancer to benefit from immunotherapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 24, 2021 Category: Cancer & Oncology Source Type: news

When to Stop Cancer Screening: Clinicians' Calculus Varies When to Stop Cancer Screening: Clinicians' Calculus Varies
Primary care physicians are more likely to use a strict age cutoff for stopping colon cancer screening than they are for stopping breast and prostate cancer screening, new data suggest.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - June 22, 2021 Category: Primary Care Tags: Family Medicine/Primary Care News Source Type: news

James Michael Tyler, Who Played Gunther on'Friends,' Has Advanced Prostate Cancer
Title: James Michael Tyler, Who Played Gunther on'Friends,'Has Advanced Prostate CancerCategory: Health NewsCreated: 6/22/2021 12:00:00 AMLast Editorial Review: 6/22/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - June 22, 2021 Category: Cancer & Oncology Source Type: news